Articles from Global Alzheimer’s Platform Foundation®

WASHINGTON, D. C. , Oct. 05, 2026 (GLOBE NEWSWIRE) -- The Global Alzheimer's Platform Foundation® (GAP), announced today that Dr. Jeffery Greenberg is joining GAP as the Medical Director and Principal Investigator of Axiom Brain Health (Axiom), GAP’s clinical research site in Tampa, FL. Dr. Greenberg succeeds Dr. Susan Steen, Axiom's longtime Medical Director and a Tampa Practitioner, who will retire at the end of the year.

Bio-Hermes-002 is a collaborative study focused on new biomarkers designed to improve diagnosis of Alzheimer's disease and dementias 

Free Memory Screenings Offered Across the Country during Alzheimer’s and Brain Awareness Month

Collaboration to accelerate the investigation of Alzheimer’s disease biomarkers with early access to Bio-Hermes-001 data

Free Memory Screenings Offered to Promote Importance of Brain Health

Bio-Hermes-002 is a collaborative study focused on new biomarkers designed to improve diagnosis of Alzheimer's disease and dementias 

Siemens Healthineers joins collaborative study focused on new biomarkers designed to improve diagnosis of Alzheimer's disease and dementias 

The Global Alzheimer’s Platform Foundation’s® (GAP) 2025 Citizen Scientist Award® recipients announced in Las Vegas

Spear Bio joins collaborative study focused on new biomarkers designed to improve diagnosis of Alzheimer's disease and dementias

WASHINGTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, to the Bio-Hermes studies. This collaboration will enhance the unique, observational platform studies that compare blood-based and digital biomarkers across a broad range of clinical cognitive conditions — along with MRI and PET images in Bio-Hermes-002 —as well as numerous races and ethnicities to generate data that may help predict, detect and diagnose Alzheimer’s disease and related dementias.

Collaboration to Improve Access to Study for Alzheimer’s Disease

Data from Most Deeply Characterized Cohort Across Alzheimer's Disease Released by Global Alzheimer’s Platform Foundation and Alzheimer’s Disease Data Initiative

WASHINGTON, July 28, 2025 (GLOBE NEWSWIRE) -- The Global Alzheimer’s Platform Foundation® (GAP), an international leader in accelerating clinical trials and improving recruitment, announced a collaboration with Genentech, a member of the Roche Group, to expand access to clinical trials for communities underrepresented in Alzheimer’s research.

IXICO joins collaborative study of new biomarkers designed to improve diagnosis of Alzheimer's disease and dementias 

WASHINGTON, May 20, 2025 (GLOBE NEWSWIRE) -- The Global Alzheimer’s Platform Foundation® (GAP) applauds the FDA's clearance of the first blood test to diagnose Alzheimer’s disease. Fujirebio’s Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio invitro diagnostic (IVD) represents the first blood-based test available to physicians and their patients for early detection of amyloid plaques associated with Alzheimer’s—a critical element in accurately diagnosing Alzheimer’s disease (AD). This new test presents a faster, less invasive and much more accessible method for diagnosis, in contrast with tests based on a PET scan or collection of cerebral spinal fluid (CSF).

Global Researchers Recognized for Trailblazing Projects in First-of-Its-Kind Data Competition

Washington D.C., Feb. 28, 2025 (GLOBE NEWSWIRE) -- The Global Alzheimer’s Platform Foundation® (GAP) proudly announced the 2024 National Citizen Scientist Awards® elevated honorees at their 2025 GAP-Net Site Optimization Conference in Miami, Florida. GAP’s Citizen Scientist Awards (CSA) celebrate the contributions of individuals who make a difference by volunteering in clinical trials for neurodegenerative diseases.

Washington D.C., Feb. 18, 2025 (GLOBE NEWSWIRE) -- The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Roche to the Bio-Hermes-002 study. This collaboration will enhance this unique, observational platform study that compares blood-based and digital biomarkers across a broad range of clinical cognitive conditions, MRI and PET images as well as numerous races and ethnicities in order to generate data that may help predict, detect and diagnose Alzheimer’s disease and related dementias. 

Collaboration to accelerate the investigation of Alzheimer’s disease biomarkers with early access to Bio-Hermes-001 data

Tampa, Fla., Jan. 24, 2025 (GLOBE NEWSWIRE) -- Axiom Brain Health (Axiom) and the Global Alzheimer’s Platform Foundation® (GAP) celebrated the next chapter in neurodegenerative research at the launch of the newly renovated site on Thursday, January 23. The expansion of the research facility accommodates the growing need for more research of Alzheimer’s, Multiple Sclerosis, Parkinson’s, and other life-threatening neurodegenerative diseases. 

Washington D.C., Jan. 23, 2025 (GLOBE NEWSWIRE) -- The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Beckman Coulter Diagnostics as a strategic partner in the Bio-Hermes-002 study. This first-time collaboration will enhance this unique, observational platform study that compares blood-based and digital biomarkers across a broad range of clinical cognitive conditions, MRI and PET images as well as numerous races and ethnicities in order to generate data that may help predict, detect and diagnose Alzheimer’s disease and related dementias.  

Lilly joins collaborative study of new biomarkers designed to improve diagnosis of Alzheimer's disease and dementias across diverse populations

Global Alzheimer’s Platform Foundation Announces Strategic Partnerships for the Transformative Bio-Hermes-002 Study

Partnership to Cultivate Best-In Class Clinical Research Services for Alzheimer’s disease and related dementias

The results of the Bio-Hermes study appear in Alzheimer's & Dementia showing how new Alzheimer’s detecting blood tests perform across a broad range of races and ethnicities for the first time.